2. Signaling Pathways
  3. GPCR/G Protein
  4. Leukotriene Receptor

Leukotriene Receptor

Leukotriene Receptor

Related Products

PDF 0.82 MB

Leukotriene Receptor (cys-LTs) are a family of potent bioactive lipids that act through two structurally divergent G protein-coupled receptors, termed the CysLT1 and CysLT2 receptors. The cysteinyl leukotrienes LTC4, LTD4, and LTE4 are important mediators of human bronchial asthma. Leukotriene Receptor is a member of the superfamily of G protein-coupled receptors and uses a phosphatidylinositol-calcium second messenger system. Activation of CysLT1 by LTD4 results in contraction and proliferation of smooth muscle, oedema, eosinophil migration and damage to the mucus layer in the lung. Leukotriene receptor antagonists, called LTRAs for short, are a class of oral medication that is non-steroidal. They may also be referred to as anti-inflammatory bronchoconstriction preventors. LTRAs work by blocking a chemical reaction that can lead to inflammation in the airways.

Leukotriene Receptor Isoform Specific Products:

Leukotriene Receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-W766920
    Olsalazine Disodium-13C12
    Olsalazine disodium-13C12 is the 13C-labeled Olsalazine disodium (HY-B0174). Olsalazine Disodium is an anti-inflammatory compound that works in inflammatory bowel disease and ulcerative colitis.
    Olsalazine Disodium-<sup>13</sup>C<sub>12</sub>
  • HY-123575
    LY 245769
    		Inhibitor
    LY 245769, a omega-trifluoro analog, is a leukotriene E4 (LTE4) inhibitor. LY 245769 interfers the omega-oxidation of N-acetyl-LTE4 and leukotriene B4 (LTB4) with IC50s of 4 μM.
    LY 245769
  • HY-105358
    CP-288886
    		Antagonist
    CP-288886 is a cysLT1 receptor antagonist with a Ki value of 0.004 μM. CP-288886 exhibits comparable activity to Zafirlukast (HY-17492) and Pranlukast (HY-B0290). CP-288886 inhibits calcium mobilization with an IC50 of 0.0005 μM in human U937 cells. CP-288886 has high oral bioavailability. CP-288886 possesses anti-asthmatic activity in a guinea pig asthma model and can be used for the research of diseases such as asthma.
    CP-288886
  • HY-13315S
    Montelukast-d6
    		Antagonist
    Montelukast-d6 is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage.
    Montelukast-d<sub>6</sub>
  • HY-142521
    BLT2 probe 1
    BLT2 probe 1 (compound 13) is a fluorescent probe based on the synthetic BLT2 agonist CAY10583. BLT2 is a promising target for diabetic wound healing and gastrointestinal lesions. BLT2 probe 1 is suitable to investigate the pharmacology of BLT2 receptor ligands in a variety of assay systems.
    BLT2 probe 1
  • HY-113758
    LY 163443
    		Antagonist
    LY 163443 is a selective antagonist of leukotrienes D4 (LTD4) and E4 (LTE4). LY 163443 can antagonize LTD4-induced contractions of guinea pig ileum, trachea, and lung parenchyma. LY 163443 also inhibits tracheal contractions to LTE4.
    LY 163443
  • HY-105426
    L-695499
    		Antagonist
    L-695499 is a potent and orally active leukotriene D4 receptor antagonist. L-695499 can be used for the researches of inflammation and immunology.
    L-695499
  • HY-120931
    LY329146
    		Inhibitor
    LY329146, a Raloxifene (HY-13738) analog, is multidrug resistance protein (MRP1) inhibitor. LY329146 inhibits leucotriene C4 ( LTC4) transport with an IC50 of 0.8 μM.
    LY329146
  • HY-105483
    MDL 43291
    		Antagonist
    MDL 43291 is a competitive leukotriene (LT) receptor antagonist. MDL 43291 antagonize LTD4 and LTE4 with pA2 of 6.7. MDL 43291 does not antagonize histamine, carbachol or substance P. MDL 43291 can be used for the researches of inflammation and immunology, such as asthma.
    MDL 43291
  • HY-N15230
    Torososide B
    Torososide B is an antiallergic compound that inhibits calcium ionophore A-induced leukotriene release from rat peritoneal mast cells.
    Torososide B
  • HY-106806
    NZ-107
    		Antagonist 99.33%
    NZ-107 is an orally active leukotriene receptor antagonist. NZ-107 can inhibit anaphylaxis reaction. NZ-107 can be used for the researches of inflammation and immunology.
    NZ-107
  • HY-149082
    LTB4 antagonist 1
    		Antagonist
    LTB4 antagonist 1, a carboxamide-acid compound, is a potent Leukotriene B4 (LTB4) antagonist with an IC50 of 288 nM. LTB4 antagonist 1 has significant anti-inflammatory properties.
    LTB4 antagonist 1
  • HY-182515
    U-19052
    		Antagonist
    U-19052 is a selective competitive peptidoleukotriene D/E receptor antagonist. U-19052 acts as a reversible antagonist that not affecting responses to non-leukotriene agonists. U-19052 does not exhibit agonist activity or induce contraction in guinea pig tracheal or ileal strips. U-19052 is a leukotriene antagonist developed by modifying leukotriene chemical structure. U-19052 can be used for the research of allergic asthma and hypersensitivity diseases.
    U-19052
  • HY-134123
    Lipoxin B4 methyl ester
    Lipoxin B4 (LXB4) methyl ester is a lipid soluble prodrug form of the transcellular metabolite LXB4. LXB4 is a positional isomer of LXA4 produced by the metabolism of 15-HETE or 15-HpETE by human leukocytes. At a concentration of 100 nM, LXB4 inhibits polymorphonuclear leukocyte (PMN) migration stimulated by leukotriene B4 (LTB4; Item No. 20110) and inhibits LTB4-induced adhesion of PMNs with an IC50 value of 0.3 nM.
    Lipoxin B4 methyl ester
  • HY-100173
    DW-1350
    		Antagonist
    DW-1350 is a LTB4 receptor antagonist.
    DW-1350
  • HY-105933
    L-652343
    		Inhibitor
    L-652343 is a dual cyclooxygenase/lipoxygenase inhibitor. L-652343 can inhibit the production of LTB4 in isolated human polymorphonuclear leukocytes treated with Calcimycin (HY-N6687) (IC50: 1.4 μM), but it is inactive in whole blood. L-652343 can be used in the research of inflammatory and immune diseases.
    L-652343
  • HY-120502
    5-LOX-IN-6
    		Inhibitor
    5-LOX-IN-6 (compound 11a) is a direct and reversible inhibitor of 5-lipoxygenase (5-LO). 5-LOX-IN-6 inhibits 5-LO activity in human neutrophils and recombinant human 5-LO with IC50 values of 0.23 and 0.086 µM, respectively. 5-LOX-IN-6 prevents leukotriene biosynthesis. 5-LOX-IN-6 can be used for inflammatory and allergic disorders research.
    5-LOX-IN-6
  • HY-112742
    CP-195543
    		Antagonist 98.86%
    CP-195543 is a potent, selective and orally active leukotriene B4 (LTB4) receptor antagonist with IC50s of 6.8, 37.0 nM for human neutrophils and murine spleen membranes, respectively. CP-195543 blocks CD11b up-regulation. CP-195543 inhibits LTB4-mediated neutrophil infiltration.
    CP-195543
  • HY-105712
    CGP 57698
    		Antagonist
    CGP 57698 is an efficient CysLT receptor (Ki = 5.7 nM) antagonist. CGP 57698 can effectively counteract bronchoconstriction caused by LTD4. CGP 57698 can be used for research on asthma or allergic conditions.
    CGP 57698
  • HY-N1942R
    5-O-Demethylnobiletin (Standard)
    		Inhibitor
    5-O-Demethylnobiletin (Standard) is the analytical standard of 5-O-Demethylnobiletin. This product is intended for research and analytical applications. 5-O-Demethylnobiletin (5-Demethylnobiletin), a polymethoxyflavone isolated from Citrus jambhiri Lush., is a direct inhibition of 5-LOX (IC50=0.1 μM), without affecting the expression of COX-2. 5-O-Demethylnobiletin (5-Demethylnobiletin) has anti-inflammatory activity, inhibits leukotriene B (4)(LTB4) formation in rat neutrophils and elastase release in human neutrophils with an IC50 of 0.35 μM.
    5-O-Demethylnobiletin (Standard)
Cat. No. Product Name / Synonyms Application Reactivity
Leukotriene Receptor Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.